| Document |
Document Title |
|
WO/2002/055501A2 |
Selected compounds of formula (I), wherein each of A?1¿ and A?2¿ is independently C or N; wherein A?1¿-A?2¿ form part of a ring A selected from 5- or 6- membered heteroaryl; wherein X is; wherein Z is oxygen or sulfur; are effective ...
|
|
WO/2002/051814A1 |
This invention relates to compounds of the formula (I) in which R?1¿, R?2¿, R?3¿, X and Q are as defined above and their use as PDE IV inhibitors.
|
|
WO2001064652A9 |
The invention relates to the field of erythropoiesis and, in particular, relates to 5-methyldihydropyridazinones of general formula (I) and to the use thereof as medicaments, preferably for the prophylaxis of and/or for combating anemias.
|
|
WO/2002/050045A1 |
This invention relates to compounds of formula I their salts, and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions comprising these compounds and their use in the treatment of picornavirus infections in mammal...
|
|
WO/2002/046161A1 |
Novel substituted carboxylic acid derivatives which bind as ligand to human peroxisome proliferator activated receptor (PPAR) to activate the receptor and thereby exhibit potent effects of decreasing neutral fat, cholesterol, and blood s...
|
|
WO/2002/044157A2 |
Compounds of formula 1, 2, and 3 where A¿1? is C(R¿4?)or N; A¿2? is C(R¿5?) or S; R¿1? is H, lower alkyl, halo, or a carbonyl; R¿2? is H, lower alkyl, acyl, or forms a double bond with an adjacent ring atom; R¿3? is H, lower alkyl...
|
|
WO/2002/042257A1 |
The invention relates to substituted cyclohexane derivates of formula (I), a method for the production thereof and the use thereof in medicaments, particularly for preventing and/or treating cardiovascular diseases, diseases of the uroge...
|
|
WO/2002/040025A1 |
The invention relates to the use of mitochondrial K¿ATP? channel openers, particularly compounds of general formula (I), for the treatment or prevention of inflammation by inducing apoptosis or inflammatory cells.
|
|
WO/2002/036576A1 |
The use of a compound of the formula: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of PARP, wherein: A and B together represent an optional...
|
|
WO/2002/030405A2 |
This invention relates to use of the combined action of a nicotinic acetylcholine receptor agonist and a monoaminergic substance for the treatment of affective disorders, as well as to pharmaceutical compositions comprising these substan...
|
|
WO2002012210A9 |
The invention concerns compounds of formula (I) wherein: R1 represents a radical of formula (a) or (b); Y represents a CH2 radical or a sulphur atom; R5 represents a hydroxy radical, an alkoxy radical, a NH-OH radical, or a N(R8)(R9) rad...
|
|
WO/2002/026743A1 |
The present invention is directed to novel pyridazine compounds of the formula (I) as well as pharmaceutically and pharmaceutically acceptable salts, and hydrates thereof; to a process for their preparation, their use and pharmaceutical ...
|
|
WO/2002/024635A2 |
The present invention relates to a compound formula (I) wherein X¿1? is bond or -O-CH¿2?-, (II) or (III) R?1¿ is hydrogen or an amino protective group, a is phenyl, indolyl or carbazolyl, each of which may be substituted with one or t...
|
|
WO/2002/024613A2 |
The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.
|
|
WO/2002/022587A1 |
Provided are novel compounds exhibiting excellent inhibitory activities against AMPA receptor and/or kainate receptor, i.e., compounds of the general formula (I), salts thereof, or hydrates of both wherein A?1¿, A?2¿ and A?3¿ are each...
|
|
WO/2002/018339A2 |
A compound according to Formula (One) is provided and a process to used such compound to control insects is provided wherein A represents a five or six membered heterocyclic ring containing at least one heteroatom selected from the group...
|
|
WO/2002/015884A2 |
A molded article such as a tablet is provided for administration to an oral cavity of a subject to treat or prevent a cyclooxygenase-2 mediated condition, disorder or disease. The molded article comprises a moldable blend of a therapeuti...
|
|
WO/2002/012199A1 |
Pleuromutilin compounds of formula (I), (II) in which: R?1¿ is: a 5- or 6-membered aromatic or heteroaromatic ring attached via a ring carbon atom, preferably pyridyl, and comprising a substituent selected from halo, R?7¿O-, R?7¿S- or...
|
|
WO/2002/010154A2 |
This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparat...
|
|
WO/2002/005815A1 |
There is provided a pharmaceutical composition suitable for topical administration to an eye which contains a selective COX-2 inhibitory drug or nanoparticles of a drug of low water solubility, in a concentration effective for treatment ...
|
|
WO/2002/006259A1 |
The invention relates to novel heterocyclic fluoralkenyl thioethers of formula (I) wherein m represents whole numbers from 3 to 10, n represents 0, 1 or 2, and Het represents the following respectively and optionally substituted grouping...
|
|
WO/2002/005848A2 |
The present invention provides methods for the treatment and prevention of ocular COX-2 mediated disorders using COX-2 inhibitors.
|
|
WO/2002/005834A2 |
The present invention is directed to the sue of at least one thyroid hormone compound or thyroid hormone-like agonist compound in the preparation of a topical medicament for the treatment of a dermatological condition affecting the dermi...
|
|
WO/2002/004427A1 |
Compounds of the general formula (I) or salts thereof; and drugs containing the compounds or the salts: (I) [wherein R?1¿ is optionally substituted phenyl, pyridyl, or the like; R?2¿ is lower alkoxy, lower alkylthio, lower alkylsulfiny...
|
|
WO/2002/004403A1 |
The invention relates to substituted piperazine derivatives of general formula (I), wherein R?1¿ to R?7¿ have the meanings given in claim no. 1, isomers thereof and salts thereof, especially physiologically compatible salts thereof, wh...
|
|
WO/2002/000661A1 |
A compound of Formula (I) wherein R?1¿, R?2¿ and R?3¿ are as defined above, useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3.
|
|
WO/2002/000622A2 |
The present invention relates to a compound of formula (I): wherein X¿1? is bond or -OCH¿2?-; X¿2? is -(CH¿2?)¿n?-, in which n is 1 or 2; X¿3? is bond, -O- or -NH-; R?1¿ is phenyl, indolyl or carbazolyl, each of which is optionall...
|
|
WO/2002/000220A1 |
Levosimendan, or (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phe
nyl]hydrazono]propanedinitrile, which has been previously suggested for the treatment of congestive heart failure is useful in the treatment of septic shock.
|
|
WO/2001/094319A1 |
The compounds of formula I in which Ar¿1?, A, R6, R7, R8 and Ar¿2? have the meanings as given in the description are novel effective bronchial therapeutics.
|
|
WO/2001/092258A1 |
Disclosed are compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein n, R¿1?, R¿2?, R¿3?, W, Q and X are defined herein, which compounds bind with high selectivity and high affinity ...
|
|
WO/2001/090071A2 |
The invention relates to novel substituted iminoazines of general formula (I), in which R?1¿, R?2¿, R?3¿, R?4¿, Z?1¿, Z?2¿ and Z?3¿ are defined as cited in the description. The invention also relates to several methods and interme...
|
|
WO/2001/087845A2 |
A compound of the formula (I): wherein A is a hydrogen atom, an optionally substituted, unsaturated, N-containing heterocyclic group or a group of the formula (a) : wherein R is an optionally substituted aryl group or an optionally subst...
|
|
WO/2001/087850A1 |
The compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof is described. Also described are processes for its preparation, pharmaceutical compositions containing it and its use in producing...
|
|
WO/2001/085670A1 |
Compounds represented by the general formula (I) or pharmacologically acceptable salts thereof which have excellent effects of lowering neutral fat level and non-HDL cholesterol level in the blood, inhibiting or suppressing the accumulat...
|
|
WO/2001/083459A2 |
Novel uracil substituted phenyl sulfamoyl carboxamides (I) and salts thereof, where A = oxygen or sulfur; X?1¿ = H, halogen, C¿1?-C¿4?-alkyl; X?2¿ = H, CN, CS-NH¿2?, halogen, C¿1?-C¿4?-alkyl, C¿1?-C¿4?-haloalkyl; X?3¿ = H, CN, ...
|
|
WO/2001/083458A2 |
This invention provides a short, asymmetric synthesis of piperazic acid and derivatives thereof, whereby either the (3S)- or (3R)-enantiomeric form may be obtained with high optical purity. (3S)-piperazic acid is derived from D-glutamic ...
|
|
WO/2001/083427A1 |
To provide PPAR$g(g) modulators seemingly usable in remedies for involutional osteoporosis which inhibit the accelerated differentiation of adipocytes and promote the formation and differentiation of osteoblasts from stem cells, or remed...
|
|
WO/2001/083434A2 |
This invention relates to anti-inflammatory and analgesic compounds, especially to certain p-(sulfonyl)phenyl amino derivatives, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compound...
|
|
WO/2001/081318A1 |
Compounds of formula (II) or a pharmaceutically acceptable salt thereof wherein, A is (a) Cl, (b) Br, (c) CN, (d) NO¿2?, or (e) F; are useful for treatment or prevention of herpes viruses.
|
|
WO/2001/079157A1 |
Compounds having the formula are methionine aminopeptidase type 2 (MetAP2) inhibitors and are useful for inhibiting angiogenesis. Also disclosed are MetAP2-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.
|
|
WO/2001/079184A1 |
Compounds of the general formula (1), prodrugs thereof, or pharmaceutically acceptable salts of both exhibit poly(ADP-ribose) polymerase (PARP) inhibiting activity and are useful as remedies for diseases due to enhanced PARP activity, e....
|
|
WO/2001/079182A1 |
The invention relates to 2-phenyl-2H-pyridazine-3-ones of general formula (I), wherein the variables R?1¿, R?2¿, X, Y and Z have the following meanings: X represents halogen; Y represents fluorine or chlorine; Z represents oxygen; R?1Â...
|
|
WO/2001/079183A1 |
The invention relates to 2-phenyl-2H-pyridazine-3-ones of general formula (I), wherein the variables R?1¿, R?2¿ and X have the following meanings: X represents halogen; R?1¿ represents hydrogen or C¿1?-C¿4? alkyl, and; R?2¿ represe...
|
|
WO/2001/079181A2 |
Substituted dihydrophthalazine sulfur containing compositions are provided which are active as non-NMDA ionotropic excitatory amino acid (EAA) receptor antagonists. The compositions are useful for treating disorders associated with exces...
|
|
WO/2001/079177A1 |
The present invention relates to N-substituted cyclic aza compounds, pharmaceutical compositions comprising such compounds, and methods of their use for effecting neuronal activities.
|
|
WO/2001/076530A2 |
This invention relates to novel compounds and compositions thereof useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
|
|
WO/2001/074788A1 |
2-(S)-hydroxymutilin carbamate derivatives of formula (I), in which R?1¿ is a 5- or 6-membered optionally substituted heteroaryl group; and R?2¿ is vinyl or ethyl, are useful in the treatment of bacterial infections.
|
|
WO/2001/072305A1 |
The invention relates to medicine, in particular to medicaments influencing an immune system and to the pharmaceutical production of said medicaments. The aim of the invention is to develop a medicinal preparation of sodium salt 5-amino-...
|
|
WO/2001/070706A2 |
A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compounds are particularly effective in the treatment or prevention of herpes viruses.
|
|
WO/2001/068619A1 |
Diarylamines, such as 5-amide substituted diarylamines of formula (I) or formula (II) wherein A is hydroxy, C¿1-6? alkoxy, or NR¿6?OR¿7?; X is OR¿12?, NR¿13?R¿12?, or NR¿14?; inhibitors of MEK and are useful in the treatment of a ...
|
